TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for infectious diseases worldwide. More Details
Flawless balance sheet with weak fundamentals.
Share Price & News
How has TaiGen Biopharmaceuticals Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 4157 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: 4157's weekly volatility has decreased from 10% to 5% over the past year.
7 Day Return
1 Year Return
Return vs Industry: 4157 underperformed the TW Biotechs industry which returned 22.8% over the past year.
Return vs Market: 4157 underperformed the TW Market which returned 31.6% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is TaiGen Biopharmaceuticals Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StWe're Not Very Worried About TaiGen Biopharmaceuticals Holdings' (GTSM:4157) Cash Burn Rate
4 months ago | Simply Wall StHere's Why We're Not Too Worried About TaiGen Biopharmaceuticals Holdings' (GTSM:4157) Cash Burn Situation
7 months ago | Simply Wall StHere's Why We're Not Too Worried About TaiGen Biopharmaceuticals Holdings's (GTSM:4157) Cash Burn Situation
Is TaiGen Biopharmaceuticals Holdings undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 4157's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 4157's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 4157 is unprofitable, so we can't compare its PE Ratio to the TW Biotechs industry average.
PE vs Market: 4157 is unprofitable, so we can't compare its PE Ratio to the TW market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 4157's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 4157 is overvalued based on its PB Ratio (24.4x) compared to the TW Biotechs industry average (4.8x).
How is TaiGen Biopharmaceuticals Holdings forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as TaiGen Biopharmaceuticals Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine TaiGen Biopharmaceuticals Holdings's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has TaiGen Biopharmaceuticals Holdings performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 4157 is currently unprofitable.
Growing Profit Margin: 4157 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 4157 is unprofitable, and losses have increased over the past 5 years at a rate of 8.1% per year.
Accelerating Growth: Unable to compare 4157's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4157 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.4%).
Return on Equity
High ROE: 4157 has a negative Return on Equity (-87.11%), as it is currently unprofitable.
How is TaiGen Biopharmaceuticals Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: 4157's short term assets (NT$470.8M) exceed its short term liabilities (NT$42.7M).
Long Term Liabilities: 4157's short term assets (NT$470.8M) exceed its long term liabilities (NT$23.3M).
Debt to Equity History and Analysis
Debt Level: 4157 is debt free.
Reducing Debt: 4157 had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 4157 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 4157 has sufficient cash runway for 1.3 years if free cash flow continues to grow at historical rates of 13.3% each year.
What is TaiGen Biopharmaceuticals Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 4157's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 4157's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 4157's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 4157's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 4157's dividend in 3 years as they are not forecast to pay a notable one for the TW market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dr. Ming-Chu Hsu, Ph.D. founded TaiGen Biotechnology Co., Ltd. in 2001. She served as Chief Consultant at TaiGen Biotechnology Co., Ltd. since January 2019 to February 2019. Dr. Hsu served as the Chief Exe...
|Vice President of Finance||4.75yrs||no data||no data|
|Vice President Corporate Development||9.42yrs||no data||no data|
|Senior Vice President of Research||15.5yrs||no data||no data|
Experienced Management: 4157's management team is seasoned and experienced (12.5 years average tenure).
|Independent Director||1.58yrs||no data||no data|
|Independent Director||9.08yrs||NT$1.04m||no data|
|Chairperson||2yrs||no data||no data|
|Independent Director||1.58yrs||no data||no data|
|Director||no data||no data||no data|
|Independent Director||no data||no data||no data|
Experienced Board: 4157's board of directors are considered experienced (8.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
TaiGen Biopharmaceuticals Holdings Limited's company bio, employee growth, exchange listings and data sources
- Name: TaiGen Biopharmaceuticals Holdings Limited
- Ticker: 4157
- Exchange: GTSM
- Founded: 2001
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: NT$13.262b
- Shares outstanding: 716.84m
- Website: https://www.taigenbiotech.com.tw
- TaiGen Biopharmaceuticals Holdings Limited
- No. 138, Xinming Road
- 7th Floor
- Taipei City
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|4157||GTSM (Taipei Exchange)||Yes||Common Stock||TW||TWD||Sep 2013|
TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for infectious diseases worldwide. Its marketed product is Taigexyn (Nemonoxacin), a novel non-fluorinated ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/01/23 08:44|
|End of Day Share Price||2021/01/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.